Table 14.2.2.1.4 Progression-Free Survival - Kaplan Meier estimation - EEP set (N = 47)

	Cohort I Murlentamab N = 13	Cohort II Murlentamab + Trifluridine/tipiracil		
		Cohort II N = 13	Cohort II (Expansion) N=21	Total N = 34
N	13	13	21	34
Progression	13 (100.0%)	13 (100.0%)	21 (100.0%)	34 (100.0%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.77	1.87	3.42	2.00
Time to event:				
Q3 [95% CI] (months)	1.84 [1.77 - 2.00]	3.84 [1.84 - 10.84]	3.58 [3.52 - 10.84]	3.61 [3.52 - 7.39]
Median [95% CI] (months)	1.77 [1.71 - 1.84]	1.87 [1.71 - 3.84]	3.42 [1.77 - 3.55]	2.00 [1.77 - 3.55]
Q1 [95% CI] (months)	1.74 [1.64 - 1.77]	1.71 [1.68 - 1.87]	1.77 [1.58 - 1.84]	1.71 [1.68 - 1.84]
Min ; Max	1.64 ; 2.00	1.68 ; 10.84	1.58 ; 11.10	1.58 ; 11.10
Survival rate at 2 months [95% CI] (%)	7.60 [0.40 ; 29.20]	46.20 [19.20 ; 69.60]	52.40 [29.60 ; 70.80]	50.00 [32.40 ; 65.20]
Survival rate at 4 months [95% CI] (%)	0.00 [0.00 ; 0.00]	23.00 [5.60 ; 47.40]	19.00 [6.00 ; 37.80]	20.60 [9.00 ; 35.40]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	23.00 [5.60 ; 47.40]	19.00 [6.00 ; 37.80]	20.60 [9.00 ; 35.40]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	7.60 [0.40 ; 29.20]	9.60 [1.60 ; 26.20]	8.80 [2.20 ; 21.20]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	7.60 [0.40 ; 29.20]	9.60 [1.60 ; 26.20]	8.80 [2.20 ; 21.20]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

Note: there was no censure
[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment

Table 14.2.2.1.5 Progression-Free Survival - Summary of events and censors over time - EEP set (N = 47)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months
Cohort I	Events (n, %)	12 (92.3%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	1 (7.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cohort II	Events (n, %)	7 (53.8%)	10 (76.9%)	10 (76.9%)	12 (92.3%)	12 (92.3%)	13 (100%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	6 (46.2%)	3 (23.1%)	3 (23.1%)	1 (7.7%)	1 (7.7%)	0 (0%)	0 (0%)
Cohort II (Expansion)	Events (n, %)	10 (47.6%)	17 (81%)	17 (81%)	19 (90.5%)	19 (90.5%)	21 (100%)	21 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	11 (52.4%)	4 (19%)	4 (19%)	2 (9.5%)	2 (9.5%)	0 (0%)	0 (0%)
Total Cohort II	Events (n, %)	17 (50%)	27 (79.4%)	27 (79.4%)	31 (91.2%)	31 (91.2%)	34 (100%)	34 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	17 (50%)	7 (20.6%)	7 (20.6%)	3 (8.8%)	3 (8.8%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment

Figure 14.2.2.1.2: Kaplan Meier curve for Progression-Free Survival: Cohort I - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Figure 14.2.2.1.3: Kaplan Meier curve for Progression-Free Survival: Cohort II - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.9879
Includes investigator's assessment as well as IRC-assessment

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Table 14.2.2.1.6 Progression-Free Survival according to the iRECIST criteria - Kaplan Meier estimation - EEP set (N = 47)

		Cohort II Murlentamab + Trifluridine/tipiracil		
	Cohort I Murlentamab N = 13	**Cohort II N = 13**	**Cohort II (Expansion) N=21**	**Total N = 34**
N	13	13	21	34
Censor	0 (0.0%)	0 (0.0%)	3 (14.3%)	3 (8.8%)
Death	11 (84.6%)	9 (69.2%)	11 (52.4%)	20 (58.8%)
Progression	2 (15.4%)	4 (30.8%)	7 (33.3%)	11 (32.4%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	5.29	8.67	6.87	7.13
Time to event:				
Q3 [95% CI] (months)	7.66 [5.19 - 20.57]	10.84 [3.98 - 12.68]	11.07 [7.13 - 13.17]	11.07 [7.49 - 12.42]
Median [95% CI] (months)	5.29 [2.30 - 7.66]	8.67 [3.12 - 10.84]	6.87 [3.42 - 11.04]	7.13 [3.55 - 10.41]
Q1 [95% CI] (months)	3.38 [1.77 - 5.29]	3.42 [1.71 - 8.67]	3.42 [1.58 - 4.24]	3.42 [1.84 - 3.98]
Min ; Max	1.77 ; 20.57	1.71 ; 12.68	1.58 ; 13.17	1.58 ; 13.17

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Table 14.2.2.1.6 Progression-Free Survival according to the iRECIST criteria - Kaplan Meier estimation - EEP set (N = 47)

		Cohort II Murlentamab + Trifluridine/tipiracil		
	Cohort I Murlentamab N = 13	Cohort II N = 13	Cohort II (Expansion) N=21	Total N = 34
Survival rate at 2 months [95% CI] (%)	84.60 [51.20 ; 96.00]	92.40 [56.60 ; 98.80]	81.00 [56.80 ; 92.40]	85.20 [68.20 ; 93.60]
Survival rate at 4 months [95% CI] (%)	69.20 [37.40 ; 87.20]	53.80 [24.80 ; 76.00]	61.00 [36.80 ; 78.20]	57.80 [39.40 ; 72.60]
Survival rate at 6 months [95% CI] (%)	30.80 [9.40 ; 55.40]	53.80 [24.80 ; 76.00]	55.40 [31.60 ; 74.00]	54.60 [36.40 ; 69.80]
Survival rate at 8 months [95% CI] (%)	23.00 [5.60 ; 47.40]	53.80 [24.80 ; 76.00]	33.20 [14.00 ; 54.00]	41.80 [24.80 ; 58.00]
Survival rate at 10 months [95% CI] (%)	23.00 [5.60 ; 47.40]	38.40 [14.00 ; 62.80]	33.20 [14.00 ; 54.00]	35.40 [19.60 ; 51.60]
Survival rate at 12 months [95% CI] (%)	7.60 [0.40 ; 29.20]	7.60 [0.40 ; 29.20]	16.60 [4.20 ; 36.40]	12.80 [4.00 ; 26.80]
Survival rate at 14 months [95% CI] (%)	7.60 [0.40 ; 29.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	7.60 [0.40 ; 29.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 18 months [95% CI] (%)	7.60 [0.40 ; 29.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 20 months [95% CI] (%)	7.60 [0.40 ; 29.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 22 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Table 14.2.2.1.7 Progression-Free Survival according to the iRECIST criteria - Summary of events and censors over time - EEP set (N = 47)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months	18 months	20 months	22 months
Cohort I	Events (n, %)	2 (15.4%)	4 (30.8%)	9 (69.2%)	10 (76.9%)	10 (76.9%)	12 (92.3%)	12 (92.3%)	12 (92.3%)	12 (92.3%)	12 (92.3%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	11 (84.6%)	9 (69.2%)	4 (30.8%)	3 (23.1%)	3 (23.1%)	1 (7.7%)	1 (7.7%)	1 (7.7%)	1 (7.7%)	1 (7.7%)	0 (0%)
Cohort II	Events (n, %)	1 (7.7%)	6 (46.2%)	6 (46.2%)	6 (46.2%)	8 (61.5%)	12 (92.3%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	12 (92.3%)	7 (53.8%)	7 (53.8%)	7 (53.8%)	5 (38.5%)	1 (7.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cohort II (Expansion)	Events (n, %)	4 (19%)	8 (38.1%)	9 (42.9%)	13 (61.9%)	13 (61.9%)	16 (76.2%)	18 (85.7%)	18 (85.7%)	18 (85.7%)	18 (85.7%)	18 (85.7%)
	Censors (n, %)	0 (0%)	2 (9.5%)	2 (9.5%)	2 (9.5%)	2 (9.5%)	3 (14.3%)	3 (14.3%)	3 (14.3%)	3 (14.3%)	3 (14.3%)	3 (14.3%)
	At-risk patients (n, %)	17 (81%)	11 (52.4%)	10 (47.6%)	6 (28.6%)	6 (28.6%)	2 (9.5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Total Cohort II	Events (n, %)	5 (14.7%)	14 (41.2%)	15 (44.1%)	19 (55.9%)	21 (61.8%)	28 (82.4%)	31 (91.2%)	31 (91.2%)	31 (91.2%)	31 (91.2%)	31 (91.2%)
	Censors (n, %)	0 (0%)	2 (5.9%)	2 (5.9%)	2 (5.9%)	2 (5.9%)	3 (8.8%)	3 (8.8%)	3 (8.8%)	3 (8.8%)	3 (8.8%)	3 (8.8%)
	At-risk patients (n, %)	29 (85.3%)	18 (52.9%)	17 (50%)	13 (38.2%)	11 (32.4%)	3 (8.8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Figure 14.2.2.1.4: Kaplan Meier curve for Progression-Free Survival according to the iRECIST criteria: Cohort I - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Figure 14.2.2.1.5: Kaplan Meier curve for Progression-Free Survival according to the iRECIST criteria: Cohort II - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.9772
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Table 14.2.2.1.8 Progression-Free Survival using investigator's assessment - Kaplan Meier estimation - EEP set (N = 47)

		Cohort II Murlentamab + Trifluridine/tipiracil		
	Cohort I Murlentamab N = 13	**Cohort II N = 13**	**Cohort II (Expansion) N=21**	**Total N = 34**
N	13	13	21	34
Death	1 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Progression according to investigator's assessment	12 (92.3%)	13 (100.0%)	21 (100.0%)	34 (100.0%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.81	3.55	3.55	3.55
Time to event:				
Q3 [95% CI] (months)	2.00 [1.77 - 4.83]	6.90 [1.87 - 14.65]	5.59 [3.58 - 10.84]	6.21 [3.58 - 9.30]
Median [95% CI] (months)	1.81 [1.71 - 2.00]	3.55 [1.71 - 6.90]	3.55 [1.81 - 4.11]	3.55 [1.84 - 4.11]
Q1 [95% CI] (months)	1.74 [1.64 - 1.81]	1.74 [1.68 - 3.55]	1.81 [1.58 - 3.52]	1.77 [1.68 - 3.42]
Min ; Max	1.64 ; 4.83	1.68 ; 14.65	1.58 ; 11.10	1.58 ; 14.65
Survival rate at 2 months [95% CI] (%)	30.80 [9.40 ; 55.40]	53.80 [24.80 ; 76.00]	66.60 [42.60 ; 82.60]	61.80 [43.40 ; 75.80]
Survival rate at 4 months [95% CI] (%)	15.40 [2.40 ; 38.80]	38.40 [14.00 ; 62.80]	33.40 [14.80 ; 53.00]	35.20 [20.00 ; 51.00]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	30.80 [9.40 ; 55.40]	23.80 [8.60 ; 43.00]	26.40 [13.20 ; 41.80]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	15.40 [2.40 ; 38.80]	19.00 [6.00 ; 37.80]	17.60 [7.20 ; 32.00]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	15.40 [2.40 ; 38.80]	9.60 [1.60 ; 26.20]	11.80 [3.80 ; 24.80]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	7.60 [0.40 ; 29.20]	0.00 [0.00 ; 0.00]	3.00 [0.20 ; 13.00]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	7.60 [0.40 ; 29.20]	0.00 [0.00 ; 0.00]	3.00 [0.20 ; 13.00]
Survival rate at 16 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

Note: there was no censure
[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.1.9 Progression-Free Survival using investigator's assessment - Summary of events and censors over time - EEP set (N = 47)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months
Cohort I	Events (n, %)	9 (69.2%)	11 (84.6%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	4 (30.8%)	2 (15.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cohort II	Events (n, %)	6 (46.2%)	8 (61.5%)	9 (69.2%)	11 (84.6%)	11 (84.6%)	12 (92.3%)	12 (92.3%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	7 (53.8%)	5 (38.5%)	4 (30.8%)	2 (15.4%)	2 (15.4%)	1 (7.7%)	1 (7.7%)	0 (0%)
Cohort II (Expansion)	Events (n, %)	7 (33.3%)	14 (66.7%)	16 (76.2%)	17 (81%)	19 (90.5%)	21 (100%)	21 (100%)	21 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	14 (66.7%)	7 (33.3%)	5 (23.8%)	4 (19%)	2 (9.5%)	0 (0%)	0 (0%)	0 (0%)
Total Cohort II	Events (n, %)	13 (38.2%)	22 (64.7%)	25 (73.5%)	28 (82.4%)	30 (88.2%)	33 (97.1%)	33 (97.1%)	34 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	21 (61.8%)	12 (35.3%)	9 (26.5%)	6 (17.6%)	4 (11.8%)	1 (2.9%)	1 (2.9%)	0 (0%)

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Figure 14.2.2.1.6: Kaplan Meier curve for Progression-Free Survival using investigator's assessment: Cohort I - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Figure 14.2.2.1.7: Kaplan Meier curve for Progression-Free Survival using investigator's assessment: Cohort II - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.9132

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Table 14.2.2.1.10 Progression-Free Survival based on the IRC-assessed response - Kaplan Meier estimation - EEP set (N = 47)

	Cohort I Murlentamab N = 13	Cohort II Murlentamab + Trifluridine/tipiracil		
		Cohort II N = 13	Cohort II (Expansion) N=21	Total N = 34
N	13	13	21	34
Censor	0 (0.0%)	0 (0.0%)	2 (9.5%)	2 (5.9%)
Death	2 (15.4%)	1 (7.7%)	3 (14.3%)	4 (11.8%)
Progression according to independent assessment	11 (84.6%)	12 (92.3%)	16 (76.2%)	28 (82.4%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.77	2.04	3.55	3.52
Time to event:				
Q3 [95% CI] (months)	1.84 [1.77 - 5.19]	3.98 [1.87 - 10.84]	7.46 [3.55 - 13.17]	6.21 [3.58 - 11.04]
Median [95% CI] (months)	1.77 [1.71 - 1.84]	2.04 [1.71 - 3.98]	3.55 [1.84 - 6.21]	3.52 [1.84 - 3.84]
Q1 [95% CI] (months)	1.74 [1.64 - 1.77]	1.74 [1.71 - 2.04]	1.84 [1.64 - 3.42]	1.81 [1.71 - 1.97]
Min ; Max	1.64 ; 5.19	1.71 ; 10.84	1.64 ; 13.17	1.64 ; 13.17
Survival rate at 2 months [95% CI] (%)	15.40 [2.40 ; 38.80]	53.80 [24.80 ; 76.00]	62.00 [38.00 ; 78.80]	58.80 [40.60 ; 73.20]
Survival rate at 4 months [95% CI] (%)	15.40 [2.40 ; 38.80]	23.00 [5.60 ; 47.40]	31.00 [12.80 ; 51.20]	28.00 [14.00 ; 43.60]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	23.00 [5.60 ; 47.40]	31.00 [12.80 ; 51.20]	28.00 [14.00 ; 43.60]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	7.60 [0.40 ; 29.20]	20.60 [6.40 ; 40.20]	15.60 [5.60 ; 29.80]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	7.60 [0.40 ; 29.20]	20.60 [6.40 ; 40.20]	15.60 [5.60 ; 29.80]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	15.40 [3.80 ; 34.20]	9.40 [2.40 ; 22.20]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.1.11 Progression-Free Survival based on the IRC-assessed response - Summary of events and censors over time - EEP set (N = 47)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months
Cohort I	Events (n, %)	11 (84.6%)	11 (84.6%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	2 (15.4%)	2 (15.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cohort II	Events (n, %)	6 (46.2%)	10 (76.9%)	10 (76.9%)	12 (92.3%)	12 (92.3%)	13 (100%)	13 (100%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	7 (53.8%)	3 (23.1%)	3 (23.1%)	1 (7.7%)	1 (7.7%)	0 (0%)	0 (0%)	0 (0%)
Cohort II (Expansion)	Events (n, %)	8 (38.1%)	14 (66.7%)	14 (66.7%)	16 (76.2%)	16 (76.2%)	17 (81%)	19 (90.5%)	19 (90.5%)
	Censors (n, %)	0 (0%)	1 (4.8%)	1 (4.8%)	1 (4.8%)	1 (4.8%)	2 (9.5%)	2 (9.5%)	2 (9.5%)
	At-risk patients (n, %)	13 (61.9%)	6 (28.6%)	6 (28.6%)	4 (19%)	4 (19%)	2 (9.5%)	0 (0%)	0 (0%)
Total Cohort II	Events (n, %)	14 (41.2%)	24 (70.6%)	24 (70.6%)	28 (82.4%)	28 (82.4%)	30 (88.2%)	32 (94.1%)	32 (94.1%)
	Censors (n, %)	0 (0%)	1 (2.9%)	1 (2.9%)	1 (2.9%)	1 (2.9%)	2 (5.9%)	2 (5.9%)	2 (5.9%)
	At-risk patients (n, %)	20 (58.8%)	9 (26.5%)	9 (26.5%)	5 (14.7%)	5 (14.7%)	2 (5.9%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Figure 14.2.2.1.8: Kaplan Meier curve for Progression-Free Survival based on the IRC-assessed response: Cohort I - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Figure 14.2.2.1.9: Kaplan Meier curve for Progression-Free Survival based on the IRC-assessed response: Cohort II - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.6027

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Table 14.2.2.1.18 Progression-Free Survival - Kaplan Meier estimation - mITT set (N = 65)

		Cohort II Murlentamab + Trifluridine/tipiracil		
	Cohort I Murlentamab N = 21	**Cohort II N = 18**	**Cohort II expansion N = 26**	**Total N = 44**
N	21	18	26	44
Death	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (2.3%)
Progression	21 (100.0%)	17 (94.4%)	26 (100.0%)	43 (97.7%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.71	1.84	1.84	1.84
Time to event:				
Q3 [95% CI] (months)	1.81 [1.74 - 1.87]	3.84 [1.84 - 7.39]	3.55 [1.97 - 7.46]	3.58 [2.04 - 6.90]
Median [95% CI] (months)	1.71 [1.41 - 1.77]	1.84 [1.71 - 3.58]	1.84 [1.71 - 3.55]	1.84 [1.71 - 3.52]
Q1 [95% CI] (months)	1.41 [0.20 - 1.64]	1.71 [0.39 - 1.74]	1.64 [0.39 - 1.77]	1.69 [1.05 - 1.71]
Min ; Max	0.20 ; 2.00	0.39 ; 10.84	0.13 ; 11.10	0.13 ; 11.10
Survival rate at 2 months [95% CI] (%)	4.80 [0.40 ; 19.80]	38.80 [17.40 ; 60.00]	42.40 [23.40 ; 60.00]	41.00 [26.40 ; 54.80]
Survival rate at 4 months [95% CI] (%)	0.00 [0.00 ; 0.00]	22.20 [7.00 ; 42.80]	15.40 [4.80 ; 31.40]	18.20 [8.60 ; 30.80]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	16.60 [4.20 ; 36.60]	15.40 [4.80 ; 31.40]	16.00 [7.00 ; 28.00]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	5.60 [0.40 ; 22.40]	7.60 [1.40 ; 21.80]	6.80 [1.80 ; 16.80]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	5.60 [0.40 ; 22.40]	7.60 [1.40 ; 21.80]	6.80 [1.80 ; 16.80]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

Note: there was no censure
[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment

Table 14.2.2.1.19 Progression-Free Survival - Summary of events and censors over time - mITT set (N = 65)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months
Cohort I	Events (n, %)	20 (95.2%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	1 (4.8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cohort II	Events (n, %)	11 (61.1%)	14 (77.8%)	15 (83.3%)	17 (94.4%)	17 (94.4%)	18 (100%)	18 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	7 (38.9%)	4 (22.2%)	3 (16.7%)	1 (5.6%)	1 (5.6%)	0 (0%)	0 (0%)
Cohort II (Expansion)	Events (n, %)	15 (57.7%)	22 (84.6%)	22 (84.6%)	24 (92.3%)	24 (92.3%)	26 (100%)	26 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	11 (42.3%)	4 (15.4%)	4 (15.4%)	2 (7.7%)	2 (7.7%)	0 (0%)	0 (0%)
Total Cohort II	Events (n, %)	26 (59.1%)	36 (81.8%)	37 (84.1%)	41 (93.2%)	41 (93.2%)	44 (100%)	44 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	18 (40.9%)	8 (18.2%)	7 (15.9%)	3 (6.8%)	3 (6.8%)	0 (0%)	0 (0%)

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator’s assessment as well as IRC-assessment

Figure 14.2.2.1.13: Kaplan Meier curve for Progression-Free Survival: Cohort I - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Figure 14.2.2.1.14: Kaplan Meier curve for Progression-Free Survival: Cohort II - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.9978
Includes investigator's assessment as well as IRC-assessment

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Table 14.2.2.1.20 Progression-Free Survival according to the iRECIST criteria - Kaplan Meier estimation - mITT set (N = 65)

		Cohort II Murlentamab + Trifluridine/tipiracil		
	Cohort I Murlentamab N = 21	**Cohort II N = 18**	**Cohort II expansion N = 26**	**Total N = 44**
N	21	18	26	44
Censor	0 (0.0%)	0 (0.0%)	3 (11.5%)	3 (6.8%)
Death	19 (90.5%)	13 (72.2%)	16 (61.5%)	29 (65.9%)
Progression	2 (9.5%)	5 (27.8%)	7 (26.9%)	12 (27.3%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	5.03	4.75	3.98	3.98
Time to event:				
Q3 [95% CI] (months)	5.88 [5.19 - 11.27]	10.41 [5.52 - 11.76]	11.04 [4.24 - 12.42]	10.41 [6.87 - 11.47]
Median [95% CI] (months)	5.03 [2.30 - 5.72]	4.75 [2.04 - 9.00]	3.98 [2.30 - 7.46]	3.98 [3.12 - 7.46]
Q1 [95% CI] (months)	2.30 [1.15 - 3.38]	2.04 [1.05 - 3.84]	2.14 [1.58 - 3.55]	2.09 [1.58 - 3.42]
Min ; Max	1.15 ; 20.57	1.05 ; 12.68	1.18 ; 13.17	1.05 ; 13.17

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Table 14.2.2.1.20 Progression-Free Survival according to the iRECIST criteria - Kaplan Meier estimation - mITT set (N = 65)

		Cohort II Murlentamab + Trifluridine/tipiracil		
	Cohort I Murlentamab N = 21	Cohort II N = 18	Cohort II expansion N = 26	Total N = 44
Survival rate at 2 months [95% CI] (%)	81.00 [56.80 ; 92.40]	77.80 [51.20 ; 91.00]	77.00 [55.60 ; 89.00]	77.20 [61.80 ; 87.00]
Survival rate at 4 months [95% CI] (%)	52.40 [29.60 ; 70.80]	50.00 [26.00 ; 70.00]	48.40 [28.00 ; 66.00]	49.00 [33.40 ; 62.80]
Survival rate at 6 months [95% CI] (%)	23.80 [8.60 ; 43.00]	44.40 [21.60 ; 65.20]	44.00 [24.20 ; 62.20]	44.20 [29.00 ; 58.20]
Survival rate at 8 months [95% CI] (%)	14.20 [3.60 ; 32.20]	38.80 [17.40 ; 60.00]	26.40 [11.00 ; 44.80]	31.80 [18.60 ; 46.00]
Survival rate at 10 months [95% CI] (%)	14.20 [3.60 ; 32.20]	27.80 [10.20 ; 48.80]	26.40 [11.00 ; 44.80]	27.00 [14.60 ; 40.80]
Survival rate at 12 months [95% CI] (%)	4.80 [0.40 ; 19.80]	5.60 [0.40 ; 22.40]	13.20 [3.40 ; 29.80]	9.80 [3.20 ; 21.00]
Survival rate at 14 months [95% CI] (%)	4.80 [0.40 ; 19.80]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	4.80 [0.40 ; 19.80]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 18 months [95% CI] (%)	4.80 [0.40 ; 19.80]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 20 months [95% CI] (%)	4.80 [0.40 ; 19.80]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 22 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Table 14.2.2.1.21 Progression-Free Survival according to the iRECIST criteria - Summary of events and censors over time - mITT set (N = 65)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months	18 months	20 months	22 months
Cohort I	Events (n, %)	4 (19%)	10 (47.6%)	16 (76.2%)	18 (85.7%)	18 (85.7%)	20 (95.2%)	20 (95.2%)	20 (95.2%)	20 (95.2%)	20 (95.2%)	21 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	17 (81%)	11 (52.4%)	5 (23.8%)	3 (14.3%)	3 (14.3%)	1 (4.8%)	1 (4.8%)	1 (4.8%)	1 (4.8%)	1 (4.8%)	0 (0%)
Cohort II	Events (n, %)	4 (22.2%)	9 (50%)	10 (55.6%)	11 (61.1%)	13 (72.2%)	17 (94.4%)	18 (100%)	18 (100%)	18 (100%)	18 (100%)	18 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	14 (77.8%)	9 (50%)	8 (44.4%)	7 (38.9%)	5 (27.8%)	1 (5.6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cohort II (Expansion)	Events (n, %)	6 (23.1%)	13 (50%)	14 (53.8%)	18 (69.2%)	18 (69.2%)	21 (80.8%)	23 (88.5%)	23 (88.5%)	23 (88.5%)	23 (88.5%)	23 (88.5%)
	Censors (n, %)	0 (0%)	2 (7.7%)	2 (7.7%)	2 (7.7%)	2 (7.7%)	3 (11.5%)	3 (11.5%)	3 (11.5%)	3 (11.5%)	3 (11.5%)	3 (11.5%)
	At-risk patients (n, %)	20 (76.9%)	11 (42.3%)	10 (38.5%)	6 (23.1%)	6 (23.1%)	2 (7.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Total Cohort II	Events (n, %)	10 (22.7%)	22 (50%)	24 (54.5%)	29 (65.9%)	31 (70.5%)	38 (86.4%)	41 (93.2%)	41 (93.2%)	41 (93.2%)	41 (93.2%)	41 (93.2%)
	Censors (n, %)	0 (0%)	2 (4.5%)	2 (4.5%)	2 (4.5%)	2 (4.5%)	3 (6.8%)	3 (6.8%)	3 (6.8%)	3 (6.8%)	3 (6.8%)	3 (6.8%)
	At-risk patients (n, %)	34 (77.3%)	20 (45.5%)	18 (40.9%)	13 (29.5%)	11 (25%)	3 (6.8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Figure 14.2.2.1.15: Kaplan Meier curve for Progression-Free Survival according to the iRECIST criteria: Cohort I - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Figure 14.2.2.1.16: Kaplan Meier curve for Progression-Free Survival according to the iRECIST criteria: Cohort II - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.9374
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Table 14.2.2.1.22 Progression-Free Survival using investigator's assessment - Kaplan Meier estimation - mITT set (N = 65)

		Cohort II Murlentamab + Trifluridine/tipiracil		
	Cohort I Murlentamab N = 21	**Cohort II N = 18**	**Cohort II expansion N = 26**	**Total N = 44**
N	21	18	26	44
Death	1 (4.8%)	1 (5.6%)	0 (0.0%)	1 (2.3%)
Progression according to investigator's assessment	20 (95.2%)	17 (94.4%)	26 (100.0%)	43 (97.7%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.71	1.86	3.47	2.64
Time to event:				
Q3 [95% CI] (months)	1.84 [1.74 - 4.60]	6.90 [1.87 - 10.84]	4.11 [3.55 - 9.30]	5.54 [3.55 - 9.07]
Median [95% CI] (months)	1.71 [1.41 - 1.81]	1.86 [1.71 - 5.49]	3.47 [1.71 - 3.61]	2.64 [1.71 - 3.58]
Q1 [95% CI] (months)	1.41 [0.20 - 1.64]	1.71 [0.39 - 1.84]	1.64 [0.39 - 1.81]	1.69 [1.05 - 1.77]
Min ; Max	0.20 ; 4.83	0.39 ; 14.65	0.13 ; 11.10	0.13 ; 14.65
Survival rate at 2 months [95% CI] (%)	19.00 [6.00 ; 37.80]	44.40 [21.60 ; 65.20]	53.80 [33.20 ; 70.60]	50.00 [34.60 ; 63.60]
Survival rate at 4 months [95% CI] (%)	9.60 [1.60 ; 26.20]	33.40 [13.60 ; 54.60]	27.00 [12.00 ; 44.40]	29.60 [17.00 ; 43.20]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	27.80 [10.20 ; 48.80]	19.20 [7.00 ; 36.00]	22.80 [11.80 ; 35.80]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	11.20 [1.80 ; 29.80]	15.40 [4.80 ; 31.40]	13.60 [5.60 ; 25.40]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	11.20 [1.80 ; 29.80]	7.60 [1.40 ; 21.80]	9.00 [2.80 ; 19.80]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	5.60 [0.40 ; 22.40]	0.00 [0.00 ; 0.00]	2.20 [0.20 ; 10.40]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	5.60 [0.40 ; 22.40]	0.00 [0.00 ; 0.00]	2.20 [0.20 ; 10.40]
Survival rate at 16 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

Note: there was no censure
[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.1.23 Progression-Free Survival using investigator's assessment - Summary of events and censors over time - mITT set (N = 65)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months
Cohort I	Events (n, %)	17 (81%)	19 (90.5%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	4 (19%)	2 (9.5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cohort II	Events (n, %)	10 (55.6%)	12 (66.7%)	13 (72.2%)	16 (88.9%)	16 (88.9%)	17 (94.4%)	17 (94.4%)	18 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	8 (44.4%)	6 (33.3%)	5 (27.8%)	2 (11.1%)	2 (11.1%)	1 (5.6%)	1 (5.6%)	0 (0%)
Cohort II (Expansion)	Events (n, %)	12 (46.2%)	19 (73.1%)	21 (80.8%)	22 (84.6%)	24 (92.3%)	26 (100%)	26 (100%)	26 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	14 (53.8%)	7 (26.9%)	5 (19.2%)	4 (15.4%)	2 (7.7%)	0 (0%)	0 (0%)	0 (0%)
Total Cohort II	Events (n, %)	22 (50%)	31 (70.5%)	34 (77.3%)	38 (86.4%)	40 (90.9%)	43 (97.7%)	43 (97.7%)	44 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	22 (50%)	13 (29.5%)	10 (22.7%)	6 (13.6%)	4 (9.1%)	1 (2.3%)	1 (2.3%)	0 (0%)

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Figure 14.2.2.1.17: Kaplan Meier curve for Progression-Free Survival using investigator's assessment: Cohort I - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Figure 14.2.2.1.18: Kaplan Meier curve for Progression-Free Survival using investigator's assessment: Cohort II - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.9143

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Table 14.2.2.1.24 Progression-Free Survival based on the IRC-assessed response - Kaplan Meier estimation - mITT set (N = 65)

	Cohort I Murlentamab N = 21	Cohort II Murlentamab + Trifluridine/tipiracil		
		Cohort II N = 18	Cohort II expansion N = 26	Total N = 44
N	21	18	26	44
Censor	0 (0.0%)	0 (0.0%)	2 (7.7%)	2 (4.5%)
Death	3 (14.3%)	3 (16.7%)	7 (26.9%)	10 (22.7%)
Progression according to independent assessment	18 (85.7%)	15 (83.3%)	17 (65.4%)	32 (72.7%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.74	1.86	3.42	2.27
Time to event:				
Q3 [95% CI] (months)	1.81 [1.77 - 5.03]	3.98 [1.87 - 7.39]	3.98 [3.55 - 12.42]	3.98 [3.55 - 7.46]
Median [95% CI] (months)	1.74 [1.45 - 1.81]	1.86 [1.71 - 3.84]	3.42 [1.81 - 3.61]	2.27 [1.81 - 3.58]
Q1 [95% CI] (months)	1.45 [0.20 - 1.68]	1.71 [1.02 - 1.84]	1.77 [1.64 - 1.97]	1.72 [1.64 - 1.84]
Min ; Max	0.20 ; 5.19	1.02 ; 10.84	1.18 ; 13.17	1.02 ; 13.17
Survival rate at 2 months [95% CI] (%)	14.20 [3.60 ; 32.20]	44.40 [21.60 ; 65.20]	57.60 [36.80 ; 74.00]	52.20 [36.60 ; 65.80]
Survival rate at 4 months [95% CI] (%)	9.60 [1.60 ; 26.20]	22.20 [7.00 ; 42.80]	24.80 [10.20 ; 42.60]	23.80 [12.40 ; 37.20]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	16.60 [4.20 ; 36.60]	24.80 [10.20 ; 42.60]	21.40 [10.60 ; 34.60]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	5.60 [0.40 ; 22.40]	16.40 [5.20 ; 33.20]	12.00 [4.40 ; 23.60]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	5.60 [0.40 ; 22.40]	16.40 [5.20 ; 33.20]	12.00 [4.40 ; 23.60]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	12.40 [3.20 ; 28.40]	7.20 [1.80 ; 17.40]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.1.25 Progression-Free Survival based on the IRC-assessed response - Summary of events and censors over time - mITT set (N = 65)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months
Cohort I	Events (n, %)	18 (85.7%)	19 (90.5%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)	21 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	3 (14.3%)	2 (9.5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cohort II	Events (n, %)	10 (55.6%)	14 (77.8%)	15 (83.3%)	17 (94.4%)	17 (94.4%)	18 (100%)	18 (100%)	18 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	8 (44.4%)	4 (22.2%)	3 (16.7%)	1 (5.6%)	1 (5.6%)	0 (0%)	0 (0%)	0 (0%)
Cohort II (Expansion)	Events (n, %)	11 (42.3%)	19 (73.1%)	19 (73.1%)	21 (80.8%)	21 (80.8%)	22 (84.6%)	24 (92.3%)	24 (92.3%)
	Censors (n, %)	0 (0%)	1 (3.8%)	1 (3.8%)	1 (3.8%)	1 (3.8%)	2 (7.7%)	2 (7.7%)	2 (7.7%)
	At-risk patients (n, %)	15 (57.7%)	6 (23.1%)	6 (23.1%)	4 (15.4%)	4 (15.4%)	2 (7.7%)	0 (0%)	0 (0%)
Total Cohort II	Events (n, %)	21 (47.7%)	33 (75%)	34 (77.3%)	38 (86.4%)	38 (86.4%)	40 (90.9%)	42 (95.5%)	42 (95.5%)
	Censors (n, %)	0 (0%)	1 (2.3%)	1 (2.3%)	1 (2.3%)	1 (2.3%)	2 (4.5%)	2 (4.5%)	2 (4.5%)
	At-risk patients (n, %)	23 (52.3%)	10 (22.7%)	9 (20.5%)	5 (11.4%)	5 (11.4%)	2 (4.5%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Figure 14.2.2.1.19: Kaplan Meier curve for Progression-Free Survival based on the IRC-assessed response: Cohort I - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Figure 14.2.2.1.20: Kaplan Meier curve for Progression-Free Survival based on the IRC-assessed response: Cohort II - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.4845

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS.sas

Table 14.2.2.2.4 Progression-Free Survival - Kaplan Meier estimation - EEP set (N = 47)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 6	**AMHRII membrane expression ≥ 20% N = 3**	**AMHRII membrane expression < 20% N = 17**	**AMHRII membrane expression ≥ 20% N = 13**
N	6	3	17	13
Progression	6 (100.0%)	3 (100.0%)	17 (100.0%)	13 (100.0%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.76	1.77	1.77	3.55
Time to event:				
Q3 [95% CI] (months)	1.84 [1.71 - 1.84]	1.87 [1.77 - 1.87]	1.87 [1.77 - 6.21]	6.90 [3.55 - 10.84]
Median [95% CI] (months)	1.76 [1.64 - 1.84]	1.77 [1.77 - 1.87]	1.77 [1.71 - 1.87]	3.55 [2.04 - 6.90]
Q1 [95% CI] (months)	1.71 [1.64 - 1.77]	1.77 [1.77 - 1.87]	1.71 [1.64 - 1.74]	3.42 [1.58 - 3.55]
Min ; Max	1.64 ; 1.84	1.77 ; 1.87	1.64 ; 7.46	1.58 ; 10.84
Survival rate at 2 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	17.60 [4.40 ; 38.40]	84.60 [51.20 ; 96.00]
Survival rate at 4 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	11.80 [2.00 ; 31.20]	30.80 [9.40 ; 55.40]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	11.80 [2.00 ; 31.20]	30.80 [9.40 ; 55.40]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	15.40 [2.40 ; 38.80]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	15.40 [2.40 ; 38.80]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Hazard ratio [95% CI, 2-sided]				2.608 [1.192 - 5.709]

Note: there was no censure
[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment

Table 14.2.2.2.5 Progression-Free Survival - Summary of events and censors over time - EEP set (N = 47)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months
C1 - AMHRII < 20%	Events (n, %)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C1 - AMHRII >= 20%	Events (n, %)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII < 20%	Events (n, %)	14 (82.4%)	15 (88.2%)	15 (88.2%)	17 (100%)	17 (100%)	17 (100%)	17 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	3 (17.6%)	2 (11.8%)	2 (11.8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII >= 20%	Events (n, %)	2 (15.4%)	9 (69.2%)	9 (69.2%)	11 (84.6%)	11 (84.6%)	13 (100%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	11 (84.6%)	4 (30.8%)	4 (30.8%)	2 (15.4%)	2 (15.4%)	0 (0%)	0 (0%)

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator’s assessment as well as IRC-assessment

Figure 14.2.2.2.2: Kaplan Meier curve for Progression-Free Survival: Cohort I - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.2660
Includes investigator's assessment as well as IRC-assessment

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Figure 14.2.2.2.3: Kaplan Meier curve for Progression-Free Survival: Cohort II - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.0186
Includes investigator's assessment as well as IRC-assessment

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Table 14.2.2.2.6 Progression-Free Survival according to the iRECIST criteria - Kaplan Meier estimation - EEP set (N = 47)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 6	**AMHRII membrane expression ≥ 20% N = 3**	**AMHRII membrane expression < 20% N = 17**	**AMHRII membrane expression ≥ 20% N = 13**
N	6	3	17	13
Censor	0 (0.0%)	0 (0.0%)	1 (5.9%)	1 (7.7%)
Death	6 (100.0%)	2 (66.7%)	11 (64.7%)	7 (53.8%)
Progression	0 (0.0%)	1 (33.3%)	5 (29.4%)	5 (38.5%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	6.60	5.03	3.98	8.67
Time to event:				
Q3 [95% CI] (months)	10.48 [3.38 - 20.57]	5.88 [1.77 - 5.88]	10.41 [3.98 - 11.47]	11.76 [7.49 - 12.68]
Median [95% CI] (months)	6.60 [2.30 - 20.57]	5.03 [1.77 - 5.88]	3.98 [2.14 - 9.00]	8.67 [3.42 - 11.76]
Q1 [95% CI] (months)	3.38 [2.30 - 7.66]	1.77 [1.77 - 5.88]	3.12 [1.71 - 3.84]	3.55 [1.58 - 8.67]
Min ; Max	2.30 ; 20.57	1.77 ; 5.88	1.71 ; 11.47	1.58 ; 12.68

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Table 14.2.2.2.6 Progression-Free Survival according to the iRECIST criteria - Kaplan Meier estimation - EEP set (N = 47)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 6	**AMHRII membrane expression ≥ 20% N = 3**	**AMHRII membrane expression < 20% N = 17**	**AMHRII membrane expression ≥ 20% N = 13**
Survival rate at 2 months [95% CI] (%)	100.00 [100.00 ; 100.00]	66.60 [5.40 ; 94.60]	82.40 [54.80 ; 94.00]	92.40 [56.60 ; 98.80]
Survival rate at 4 months [95% CI] (%)	66.60 [19.40 ; 90.40]	66.60 [5.40 ; 94.60]	44.60 [20.40 ; 66.40]	69.20 [37.40 ; 87.20]
Survival rate at 6 months [95% CI] (%)	50.00 [11.00 ; 80.40]	0.00 [0.00 ; 0.00]	38.20 [15.80 ; 60.60]	69.20 [37.40 ; 87.20]
Survival rate at 8 months [95% CI] (%)	33.40 [4.60 ; 67.60]	0.00 [0.00 ; 0.00]	31.80 [11.80 ; 54.40]	53.80 [24.80 ; 76.00]
Survival rate at 10 months [95% CI] (%)	33.40 [4.60 ; 67.60]	0.00 [0.00 ; 0.00]	25.40 [8.00 ; 47.80]	46.20 [19.20 ; 69.60]
Survival rate at 12 months [95% CI] (%)	16.60 [0.80 ; 51.60]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	23.00 [5.60 ; 47.40]
Survival rate at 14 months [95% CI] (%)	16.60 [0.80 ; 51.60]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	16.60 [0.80 ; 51.60]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 18 months [95% CI] (%)	16.60 [0.80 ; 51.60]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 20 months [95% CI] (%)	16.60 [0.80 ; 51.60]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 22 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Hazard ratio [95% CI, 2-sided]				1.981 [0.902 - 4.348]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Table 14.2.2.2.7 Progression-Free Survival according to the iRECIST criteria - Summary of events and censors over time - EEP set (N = 47)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months	18 months	20 months	22 months
C1 - AMHRII < 20%	Events (n, %)	0 (0%)	2 (33.3%)	3 (50%)	4 (66.7%)	4 (66.7%)	5 (83.3%)	5 (83.3%)	5 (83.3%)	5 (83.3%)	5 (83.3%)	6 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	6 (100%)	4 (66.7%)	3 (50%)	2 (33.3%)	2 (33.3%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	0 (0%)
C1 - AMHRII >= 20%	Events (n, %)	1 (33.3%)	1 (33.3%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	2 (66.7%)	2 (66.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII < 20%	Events (n, %)	3 (17.6%)	9 (52.9%)	10 (58.8%)	11 (64.7%)	12 (70.6%)	16 (94.1%)	16 (94.1%)	16 (94.1%)	16 (94.1%)	16 (94.1%)	16 (94.1%)
	Censors (n, %)	0 (0%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)
	At-risk patients (n, %)	14 (82.4%)	7 (41.2%)	6 (35.3%)	5 (29.4%)	4 (23.5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII >= 20%	Events (n, %)	1 (7.7%)	4 (30.8%)	4 (30.8%)	6 (46.2%)	7 (53.8%)	10 (76.9%)	12 (92.3%)	12 (92.3%)	12 (92.3%)	12 (92.3%)	12 (92.3%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (7.7%)	1 (7.7%)	1 (7.7%)	1 (7.7%)	1 (7.7%)	1 (7.7%)
	At-risk patients (n, %)	12 (92.3%)	9 (69.2%)	9 (69.2%)	7 (53.8%)	6 (46.2%)	2 (15.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Figure 14.2.2.2.4: Kaplan Meier curve for Progression-Free Survival according to the iRECIST criteria: Cohort I - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.2154
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Figure 14.2.2.2.5: Kaplan Meier curve for Progression-Free Survival according to the iRECIST criteria: Cohort II - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.0656
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Table 14.2.2.2.8 Progression-Free Survival using investigator's assessment - Kaplan Meier estimation - EEP set (N = 47)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 6	**AMHRII membrane expression ≥ 20% N = 3**	**AMHRII membrane expression < 20% N = 17**	**AMHRII membrane expression ≥ 20% N = 13**
N	6	3	17	13
Death	1 (16.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Progression according to investigator's assessment	5 (83.3%)	3 (100.0%)	17 (100.0%)	13 (100.0%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.76	1.87	1.84	3.58
Time to event:				
Q3 [95% CI] (months)	1.84 [1.71 - 3.38]	4.60 [1.77 - 4.60]	3.98 [1.84 - 9.30]	7.39 [3.58 - 10.84]
Median [95% CI] (months)	1.76 [1.64 - 3.38]	1.87 [1.77 - 4.60]	1.84 [1.71 - 3.98]	3.58 [3.42 - 7.39]
Q1 [95% CI] (months)	1.71 [1.64 - 1.77]	1.77 [1.77 - 4.60]	1.71 [1.64 - 1.81]	3.55 [1.58 - 3.58]
Min ; Max	1.64 ; 3.38	1.77 ; 4.60	1.64 ; 14.65	1.58 ; 10.84
Survival rate at 2 months [95% CI] (%)	16.60 [0.80 ; 51.60]	33.40 [0.80 ; 77.40]	35.20 [14.40 ; 57.00]	84.60 [51.20 ; 96.00]
Survival rate at 4 months [95% CI] (%)	0.00 [0.00 ; 0.00]	33.40 [0.80 ; 77.40]	23.60 [7.40 ; 45.00]	46.20 [19.20 ; 69.60]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	17.60 [4.40 ; 38.40]	38.40 [14.00 ; 62.80]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	11.80 [2.00 ; 31.20]	23.00 [5.60 ; 47.40]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	5.80 [0.40 ; 23.60]	15.40 [2.40 ; 38.80]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	5.80 [0.40 ; 23.60]	0.00 [0.00 ; 0.00]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	5.80 [0.40 ; 23.60]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Hazard ratio [95% CI, 2-sided]				1.656 [0.788 - 3.480]

Note: there was no censure
[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.2.9 Progression-Free Survival using investigator's assessment - Summary of events and censors over time - EEP set (N = 47)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months
C1 - AMHRII < 20%	Events (n, %)	5 (83.3%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	1 (16.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C1 - AMHRII >= 20%	Events (n, %)	2 (66.7%)	2 (66.7%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	1 (33.3%)	1 (33.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII < 20%	Events (n, %)	11 (64.7%)	13 (76.5%)	14 (82.4%)	15 (88.2%)	16 (94.1%)	16 (94.1%)	16 (94.1%)	17 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	6 (35.3%)	4 (23.5%)	3 (17.6%)	2 (11.8%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	0 (0%)
C2 - AMHRII >= 20%	Events (n, %)	2 (15.4%)	7 (53.8%)	8 (61.5%)	10 (76.9%)	11 (84.6%)	13 (100%)	13 (100%)	13 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	11 (84.6%)	6 (46.2%)	5 (38.5%)	3 (23.1%)	2 (15.4%)	0 (0%)	0 (0%)	0 (0%)

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Figure 14.2.2.2.6: Kaplan Meier curve for Progression-Free Survival using investigator's assessment: Cohort I - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.1817

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Figure 14.2.2.2.7: Kaplan Meier curve for Progression-Free Survival using investigator's assessment: Cohort II - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.2137

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Table 14.2.2.2.10 Progression-Free Survival based on the IRC-assessed response - Kaplan Meier estimation - EEP set (N = 47)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 6	**AMHRII membrane expression ≥ 20% N = 3**	**AMHRII membrane expression < 20% N = 17**	**AMHRII membrane expression ≥ 20% N = 13**
N	6	3	17	13
Censor	0 (0.0%)	0 (0.0%)	1 (5.9%)	1 (7.7%)
Death	0 (0.0%)	1 (33.3%)	1 (5.9%)	2 (15.4%)
Progression according to independent assessment	6 (100.0%)	2 (66.7%)	15 (88.2%)	10 (76.9%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.76	1.77	1.84	3.58
Time to event:				
Q3 [95% CI] (months)	1.84 [1.71 - 1.84]	5.03 [1.77 - 5.03]	3.84 [1.84 - 7.46]	10.84 [3.58 - 12.42]
Median [95% CI] (months)	1.76 [1.64 - 1.84]	1.77 [1.77 - 5.03]	1.84 [1.71 - 3.84]	3.58 [3.42 - 10.84]
Q1 [95% CI] (months)	1.71 [1.64 - 1.77]	1.77 [1.77 - 5.03]	1.71 [1.64 - 1.81]	3.55 [1.64 - 3.58]
Min ; Max	1.64 ; 1.84	1.77 ; 5.03	1.64 ; 7.46	1.64 ; 12.42
Survival rate at 2 months [95% CI] (%)	0.00 [0.00 ; 0.00]	33.40 [0.80 ; 77.40]	29.40 [10.80 ; 51.20]	92.40 [56.60 ; 98.80]
Survival rate at 4 months [95% CI] (%)	0.00 [0.00 ; 0.00]	33.40 [0.80 ; 77.40]	14.80 [2.60 ; 36.40]	46.20 [19.20 ; 69.60]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	14.80 [2.60 ; 36.40]	46.20 [19.20 ; 69.60]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	30.80 [9.40 ; 55.40]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	30.80 [9.40 ; 55.40]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	15.40 [2.40 ; 38.80]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.2.10 Progression-Free Survival based on the IRC-assessed response - Kaplan Meier estimation - EEP set (N = 47)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 6	**AMHRII membrane expression ≥ 20% N = 3**	**AMHRII membrane expression < 20% N = 17**	**AMHRII membrane expression ≥ 20% N = 13**
Hazard ratio [95% CI, 2-sided]				3.144 [1.348 - 7.331]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.2.11 Progression-Free Survival based on the IRC-assessed response - Summary of events and censors over time - EEP set (N = 47)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months
C1 - AMHRII < 20%	Events (n, %)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)	6 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C1 - AMHRII >= 20%	Events (n, %)	2 (66.7%)	2 (66.7%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	1 (33.3%)	1 (33.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII < 20%	Events (n, %)	12 (70.6%)	14 (82.4%)	14 (82.4%)	16 (94.1%)	16 (94.1%)	16 (94.1%)	16 (94.1%)	16 (94.1%)
	Censors (n, %)	0 (0%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)	1 (5.9%)
	At-risk patients (n, %)	5 (29.4%)	2 (11.8%)	2 (11.8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII >= 20%	Events (n, %)	1 (7.7%)	7 (53.8%)	7 (53.8%)	9 (69.2%)	9 (69.2%)	11 (84.6%)	12 (92.3%)	12 (92.3%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (7.7%)	1 (7.7%)	1 (7.7%)
	At-risk patients (n, %)	12 (92.3%)	6 (46.2%)	6 (46.2%)	4 (30.8%)	4 (30.8%)	1 (7.7%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Figure 14.2.2.2.8: Kaplan Meier curve for Progression-Free Survival based on the IRC-assessed response: Cohort I - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.2660

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Figure 14.2.2.2.9: Kaplan Meier curve for Progression-Free Survival based on the IRC-assessed response: Cohort II - EEP set (N = 47)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.0061

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Table 14.2.2.2.18 Progression-Free Survival - Kaplan Meier estimation - mITT set (N = 65)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 12	**AMHRII membrane expression ≥ 20% N = 4**	**AMHRII membrane expression < 20% N = 24**	**AMHRII membrane expression ≥ 20% N = 16**
N	12	4	24	16
Death	0 (0.0%)	0 (0.0%)	1 (4.2%)	0 (0.0%)
Progression	12 (100.0%)	4 (100.0%)	23 (95.8%)	16 (100.0%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.66	1.77	1.72	3.55
Time to event:				
Q3 [95% CI] (months)	1.76 [1.64 - 1.84]	1.82 [0.20 - 1.87]	1.86 [1.77 - 5.52]	5.24 [3.55 - 10.84]
Median [95% CI] (months)	1.66 [1.12 - 1.77]	1.77 [0.20 - 1.87]	1.72 [1.71 - 1.84]	3.55 [1.58 - 3.58]
Q1 [95% CI] (months)	1.26 [0.92 - 1.64]	0.99 [0.20 - 1.77]	1.69 [0.13 - 1.71]	1.61 [0.39 - 3.55]
Min ; Max	0.92 ; 1.84	0.20 ; 1.87	0.13 ; 7.46	0.39 ; 10.84
Survival rate at 2 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	16.60 [5.20 ; 33.80]	68.80 [40.40 ; 85.60]
Survival rate at 4 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	12.60 [3.20 ; 28.60]	25.00 [7.80 ; 47.20]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	8.40 [1.40 ; 23.20]	25.00 [7.80 ; 47.20]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	12.60 [2.00 ; 32.80]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	12.60 [2.00 ; 32.80]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Hazard ratio [95% CI, 2-sided]				2.042 [1.032 - 4.041]

Note: there was no censure
[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment

Table 14.2.2.2.19 Progression-Free Survival - Summary of events and censors over time - mITT set (N = 65)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months
C1 - AMHRII < 20%	Events (n, %)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C1 - AMHRII >= 20%	Events (n, %)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII < 20%	Events (n, %)	20 (83.3%)	21 (87.5%)	22 (91.7%)	24 (100%)	24 (100%)	24 (100%)	24 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	4 (16.7%)	3 (12.5%)	2 (8.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII >= 20%	Events (n, %)	5 (31.3%)	12 (75%)	12 (75%)	14 (87.5%)	14 (87.5%)	16 (100%)	16 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	11 (68.8%)	4 (25%)	4 (25%)	2 (12.5%)	2 (12.5%)	0 (0%)	0 (0%)

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator’s assessment as well as IRC-assessment

Figure 14.2.2.2.13: Kaplan Meier curve for Progression-Free Survival: Cohort I - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.2162
Includes investigator's assessment as well as IRC-assessment

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Figure 14.2.2.2.14: Kaplan Meier curve for Progression-Free Survival: Cohort II - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.0456
Includes investigator's assessment as well as IRC-assessment

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Table 14.2.2.2.20 Progression-Free Survival according to the iRECIST criteria - Kaplan Meier estimation - mITT set (N = 65)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 12	**AMHRII membrane expression ≥ 20% N = 4**	**AMHRII membrane expression < 20% N = 24**	**AMHRII membrane expression ≥ 20% N = 16**
N	12	4	24	16
Censor	0 (0.0%)	0 (0.0%)	1 (4.2%)	1 (6.3%)
Death	12 (100.0%)	3 (75.0%)	17 (70.8%)	10 (62.5%)
Progression	0 (0.0%)	1 (25.0%)	6 (25.0%)	5 (31.3%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	4.47	4.27	3.84	7.31
Time to event:				
Q3 [95% CI] (months)	7.46 [3.38 - 20.57]	5.45 [1.77 - 5.88]	7.46 [3.98 - 11.07]	11.40 [7.13 - 12.68]
Median [95% CI] (months)	4.47 [1.77 - 7.66]	4.27 [1.77 - 5.88]	3.84 [2.30 - 5.52]	7.31 [1.74 - 11.04]
Q1 [95% CI] (months)	2.28 [1.15 - 3.38]	2.64 [1.77 - 5.03]	2.22 [1.05 - 3.42]	1.89 [1.05 - 7.13]
Min ; Max	1.15 ; 20.57	1.77 ; 5.88	1.05 ; 11.47	1.05 ; 12.68

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Table 14.2.2.2.20 Progression-Free Survival according to the iRECIST criteria - Kaplan Meier estimation - mITT set (N = 65)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 12	**AMHRII membrane expression ≥ 20% N = 4**	**AMHRII membrane expression < 20% N = 24**	**AMHRII membrane expression ≥ 20% N = 16**
Survival rate at 2 months [95% CI] (%)	83.40 [48.20 ; 95.60]	75.00 [12.80 ; 96.00]	79.20 [57.00 ; 90.80]	75.00 [46.40 ; 89.80]
Survival rate at 4 months [95% CI] (%)	50.00 [20.80 ; 73.60]	50.00 [5.80 ; 84.40]	39.80 [20.40 ; 58.60]	56.20 [29.60 ; 76.20]
Survival rate at 6 months [95% CI] (%)	33.40 [10.20 ; 58.80]	0.00 [0.00 ; 0.00]	30.80 [13.80 ; 49.80]	56.20 [29.60 ; 76.20]
Survival rate at 8 months [95% CI] (%)	16.60 [2.60 ; 41.20]	0.00 [0.00 ; 0.00]	22.00 [8.00 ; 40.40]	43.80 [19.80 ; 65.60]
Survival rate at 10 months [95% CI] (%)	16.60 [2.60 ; 41.20]	0.00 [0.00 ; 0.00]	17.60 [5.60 ; 35.40]	37.60 [15.40 ; 59.80]
Survival rate at 12 months [95% CI] (%)	8.40 [0.60 ; 31.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	18.80 [4.60 ; 40.20]
Survival rate at 14 months [95% CI] (%)	8.40 [0.60 ; 31.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	8.40 [0.60 ; 31.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 18 months [95% CI] (%)	8.40 [0.60 ; 31.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 20 months [95% CI] (%)	8.40 [0.60 ; 31.20]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 22 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Hazard ratio [95% CI, 2-sided]				1.731 [0.879 - 3.409]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Table 14.2.2.2.21 Progression-Free Survival according to the iRECIST criteria - Summary of events and censors over time - mITT set (N = 65)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months	18 months	20 months	22 months
C1 - AMHRII < 20%	Events (n, %)	2 (16.7%)	6 (50%)	8 (66.7%)	10 (83.3%)	10 (83.3%)	11 (91.7%)	11 (91.7%)	11 (91.7%)	11 (91.7%)	11 (91.7%)	12 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	10 (83.3%)	6 (50%)	4 (33.3%)	2 (16.7%)	2 (16.7%)	1 (8.3%)	1 (8.3%)	1 (8.3%)	1 (8.3%)	1 (8.3%)	0 (0%)
C1 - AMHRII >= 20%	Events (n, %)	1 (25%)	2 (50%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	3 (75%)	2 (50%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII < 20%	Events (n, %)	5 (20.8%)	14 (58.3%)	16 (66.7%)	18 (75%)	19 (79.2%)	23 (95.8%)	23 (95.8%)	23 (95.8%)	23 (95.8%)	23 (95.8%)	23 (95.8%)
	Censors (n, %)	0 (0%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)
	At-risk patients (n, %)	19 (79.2%)	9 (37.5%)	7 (29.2%)	5 (20.8%)	4 (16.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII >= 20%	Events (n, %)	4 (25%)	7 (43.8%)	7 (43.8%)	9 (56.3%)	10 (62.5%)	13 (81.3%)	15 (93.8%)	15 (93.8%)	15 (93.8%)	15 (93.8%)	15 (93.8%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (6.3%)	1 (6.3%)	1 (6.3%)	1 (6.3%)	1 (6.3%)	1 (6.3%)
	At-risk patients (n, %)	12 (75%)	9 (56.3%)	9 (56.3%)	7 (43.8%)	6 (37.5%)	2 (12.5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Figure 14.2.2.2.15: Kaplan Meier curve for Progression-Free Survival according to the iRECIST criteria: Cohort I - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.4660
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Figure 14.2.2.2.16: Kaplan Meier curve for Progression-Free Survival according to the iRECIST criteria: Cohort II - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.0839
Includes investigator's assessment as well as IRC-assessment
Unconfirmed progressions are not taken into account

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Table 14.2.2.2.22 Progression-Free Survival using investigator's assessment - Kaplan Meier estimation - mITT set (N = 65)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 12	**AMHRII membrane expression ≥ 20% N = 4**	**AMHRII membrane expression < 20% N = 24**	**AMHRII membrane expression ≥ 20% N = 16**
N	12	4	24	16
Death	1 (8.3%)	0 (0.0%)	1 (4.2%)	0 (0.0%)
Progression according to investigator's assessment	11 (91.7%)	4 (100.0%)	23 (95.8%)	16 (100.0%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.66	1.82	1.79	3.56
Time to event:				
Q3 [95% CI] (months)	1.76 [1.64 - 3.38]	3.24 [0.20 - 4.60]	3.76 [1.84 - 7.36]	7.15 [3.55 - 10.84]
Median [95% CI] (months)	1.66 [1.12 - 1.77]	1.82 [0.20 - 4.60]	1.79 [1.71 - 1.87]	3.56 [1.58 - 6.90]
Q1 [95% CI] (months)	1.26 [0.92 - 1.64]	0.99 [0.20 - 1.87]	1.69 [0.13 - 1.71]	1.61 [0.39 - 3.55]
Min ; Max	0.92 ; 3.38	0.20 ; 4.60	0.13 ; 14.65	0.39 ; 10.84
Survival rate at 2 months [95% CI] (%)	8.40 [0.60 ; 31.20]	25.00 [0.80 ; 66.60]	29.20 [13.00 ; 47.60]	68.80 [40.40 ; 85.60]
Survival rate at 4 months [95% CI] (%)	0.00 [0.00 ; 0.00]	25.00 [0.80 ; 66.60]	20.80 [7.60 ; 38.60]	37.60 [15.40 ; 59.80]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	16.60 [5.20 ; 33.80]	31.20 [11.40 ; 53.60]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	8.40 [1.40 ; 23.20]	18.80 [4.60 ; 40.20]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	4.20 [0.20 ; 17.60]	12.60 [2.00 ; 32.80]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	4.20 [0.20 ; 17.60]	0.00 [0.00 ; 0.00]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	4.20 [0.20 ; 17.60]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Hazard ratio [95% CI, 2-sided]				1.478 [0.772 - 2.828]

Note: there was no censure
[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.2.23 Progression-Free Survival using investigator's assessment - Summary of events and censors over time - mITT set (N = 65)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months
C1 - AMHRII < 20%	Events (n, %)	11 (91.7%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	1 (8.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C1 - AMHRII >= 20%	Events (n, %)	3 (75%)	3 (75%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	1 (25%)	1 (25%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII < 20%	Events (n, %)	17 (70.8%)	19 (79.2%)	20 (83.3%)	22 (91.7%)	23 (95.8%)	23 (95.8%)	23 (95.8%)	24 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	7 (29.2%)	5 (20.8%)	4 (16.7%)	2 (8.3%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	0 (0%)
C2 - AMHRII >= 20%	Events (n, %)	5 (31.3%)	10 (62.5%)	11 (68.8%)	13 (81.3%)	14 (87.5%)	16 (100%)	16 (100%)	16 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	11 (68.8%)	6 (37.5%)	5 (31.3%)	3 (18.8%)	2 (12.5%)	0 (0%)	0 (0%)	0 (0%)

Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Figure 14.2.2.2.17: Kaplan Meier curve for Progression-Free Survival using investigator's assessment: Cohort I - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.1534

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Figure 14.2.2.2.18: Kaplan Meier curve for Progression-Free Survival using investigator's assessment: Cohort II - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.2683

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Table 14.2.2.2.24 Progression-Free Survival based on the IRC-assessed response - Kaplan Meier estimation - mITT set (N = 65)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 12	**AMHRII membrane expression ≥ 20% N = 4**	**AMHRII membrane expression < 20% N = 24**	**AMHRII membrane expression ≥ 20% N = 16**
N	12	4	24	16
Censor	0 (0.0%)	0 (0.0%)	1 (4.2%)	1 (6.3%)
Death	0 (0.0%)	1 (25.0%)	5 (20.8%)	4 (25.0%)
Progression according to independent assessment	12 (100.0%)	3 (75.0%)	18 (75.0%)	11 (68.8%)
Median follow-up time [95% CI] (months) [a]	Not reached	Not reached	Not reached	Not reached
Median follow-up time for survivors (months) [b]	1.66	1.77	1.84	3.56
Time to event:				
Q3 [95% CI] (months)	1.76 [1.64 - 1.84]	3.40 [0.20 - 5.03]	3.84 [1.84 - 6.21]	9.12 [3.55 - 12.42]
Median [95% CI] (months)	1.66 [1.12 - 1.77]	1.77 [0.20 - 5.03]	1.84 [1.71 - 2.50]	3.56 [1.74 - 7.39]
Q1 [95% CI] (months)	1.26 [0.92 - 1.64]	0.99 [0.20 - 1.77]	1.71 [1.05 - 1.77]	1.89 [1.02 - 3.55]
Min ; Max	0.92 ; 1.84	0.20 ; 5.03	1.05 ; 7.46	1.02 ; 12.42
Survival rate at 2 months [95% CI] (%)	0.00 [0.00 ; 0.00]	25.00 [0.80 ; 66.60]	33.40 [16.00 ; 51.80]	75.00 [46.40 ; 89.80]
Survival rate at 4 months [95% CI] (%)	0.00 [0.00 ; 0.00]	25.00 [0.80 ; 66.60]	14.20 [3.80 ; 31.80]	37.60 [15.40 ; 59.80]
Survival rate at 6 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	9.60 [1.60 ; 25.80]	37.60 [15.40 ; 59.80]
Survival rate at 8 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	25.00 [7.80 ; 47.20]
Survival rate at 10 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	25.00 [7.80 ; 47.20]
Survival rate at 12 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	12.60 [2.00 ; 32.80]
Survival rate at 14 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]
Survival rate at 16 months [95% CI] (%)	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]	0.00 [0.00 ; 0.00]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.2.24 Progression-Free Survival based on the IRC-assessed response - Kaplan Meier estimation - mITT set (N = 65)

	Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
	AMHRII membrane expression < 20% N = 12	**AMHRII membrane expression ≥ 20% N = 4**	**AMHRII membrane expression < 20% N = 24**	**AMHRII membrane expression ≥ 20% N = 16**
Hazard ratio [95% CI, 2-sided]				2.276 [1.099 - 4.714]

[a] Reverse Kaplan-Meier estimation
[b] Calculated using observed follow-up time of survivors
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Table 14.2.2.2.25 Progression-Free Survival based on the IRC-assessed response - Summary of events and censors over time - mITT set (N = 65)

		2 months	4 months	6 months	8 months	10 months	12 months	14 months	16 months
C1 - AMHRII < 20%	Events (n, %)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C1 - AMHRII >= 20%	Events (n, %)	3 (75%)	3 (75%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	At-risk patients (n, %)	1 (25%)	1 (25%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII < 20%	Events (n, %)	16 (66.7%)	20 (83.3%)	21 (87.5%)	23 (95.8%)	23 (95.8%)	23 (95.8%)	23 (95.8%)	23 (95.8%)
	Censors (n, %)	0 (0%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)	1 (4.2%)
	At-risk patients (n, %)	8 (33.3%)	3 (12.5%)	2 (8.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
C2 - AMHRII >= 20%	Events (n, %)	4 (25%)	10 (62.5%)	10 (62.5%)	12 (75%)	12 (75%)	14 (87.5%)	15 (93.8%)	15 (93.8%)
	Censors (n, %)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (6.3%)	1 (6.3%)	1 (6.3%)
	At-risk patients (n, %)	12 (75%)	6 (37.5%)	6 (37.5%)	4 (25%)	4 (25%)	1 (6.3%)	0 (0%)	0 (0%)

Patients who didn’t experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment

Figure 14.2.2.2.19: Kaplan Meier curve for Progression-Free Survival based on the IRC-assessed response: Cohort I - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.2162

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas

Figure 14.2.2.2.20: Kaplan Meier curve for Progression-Free Survival based on the IRC-assessed response: Cohort II - mITT set (N = 65)



Note: Number of patients at risk is presented under the curve
Patients who didn't experienced the analysis event and still under study follow-up have been censored at the time of the last available visit or the time of the last tumor assessment
p-value for Logrank test is 0.0223

Extraction date: 02JUL2021 / Generated on 15JUL2021 16:37 / Program: Secondary_Efficacy_PFS_OS_AMHRII.sas